A Phase 1b, Randomized, Investigator- and Participant-Blinded, Placebo-Controlled Multiple-Dose Study to Evaluate the Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Brenipatide in Healthy Participants With Overweight or Obesity
Latest Information Update: 28 Mar 2026
At a glance
- Drugs Brenipatide (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
Most Recent Events
- 28 Mar 2026 New trial record